Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Non-Current Assets: 2022-2025

Historic Non-Current Assets for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $54.1 million.

  • NewAmsterdam Pharma Co N.V's Non-Current Assets rose 4007.74% to $54.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.1 million, marking a year-over-year increase of 4007.74%. This contributed to the annual value of $1.2 million for FY2024, which is 294.44% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Non-Current Assets stood at $54.1 million for Q3 2025, which was up 19.52% from $45.3 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's Non-Current Assets' 5-year high stood at $54.1 million during Q3 2025, with a 5-year trough of $81,834 in Q2 2023.
  • Moreover, its 3-year median value for Non-Current Assets was $1.2 million (2024), whereas its average is $11.7 million.
  • Data for NewAmsterdam Pharma Co N.V's Non-Current Assets shows a peak YoY skyrocketed of 4,007.74% (in 2025) over the last 5 years.
  • Quarterly analysis of 4 years shows NewAmsterdam Pharma Co N.V's Non-Current Assets stood at $83,450 in 2022, then skyrocketed by 266.69% to $306,000 in 2023, then skyrocketed by 294.44% to $1.2 million in 2024, then skyrocketed by 4,007.74% to $54.1 million in 2025.
  • Its last three reported values are $54.1 million in Q3 2025, $45.3 million for Q2 2025, and $1.1 million during Q1 2025.